Hans‐Peter Tony

St. Michael's Hospital — Canada

Medicine · Health Sciences

40h-index7.3kcitations228works3.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Rheumatoid Arthritis Research and Therapies(84), Monoclonal and Polyclonal Antibodies Research(41), Chronic Lymphocytic Leukemia Research(37), Systemic Lupus Erythematosus Research(34), T-cell and B-cell Immunology(32)

Publications224 total

Diverging effects of tumor necrosis factor inhibitors and conventional synthetic disease-modifying antirheumatic drugs on immunosenescence and inflammageing in rheumatoid arthritis: a cross-sectional analysis
Immunity & Ageing·2025· 1 citedOpen Access
Stent Dysfunction in EUS-choledochoduodenostomy for Malignant Biliary Obstruction
Endoscopy·2025
A selective resection algorithm for large non-pedunculated colorectal polyps (LNPCPs) optimizes outcomes of endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD)
Endoscopy·2025
Long-Term Outcomes of Endoscopic Drainage Modalities in Patients with Pancreatic Fluid Collections Following Acute Pancreatitis: a multicenter retrospective cohort study
Endoscopy·2025
Vaccination status of patients with primary immunodeficiencies in Germany—a multicentric epidemiologic analysis
Zeitschrift für Rheumatologie·2024
Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register
RMD Open·2023· 50 citedOpen Access
Subcutaneous abatacept for the treatment of rheumatoid arthritis in routine clinical practice in Germany, Austria, and Switzerland: 2-year retention and efficacy by treatment line and serostatus
Clinical Rheumatology·2023· 3 citedOpen Access
Physical Function of RA patients Tapering Treatment—A Post Hoc Analysis of the Randomized Controlled RETRO Trial
Journal of Clinical Medicine·2023· 2 citedOpen Access
Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial
The Lancet Rheumatology·2023· 74 cited
Physical Function of RA patients tapering treatment: A Post-Hoc Analysis of the Randomized Controlled RETRO Trial
Preprints.org·2023· 2 citedOpen Access
The efficacy and safety of systemic corticosteroids as first line treatment for granulomatous lymphocytic interstitial lung disease
Journal of Allergy and Clinical Immunology·2022· 22 cited
Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA)
Journal of Clinical Medicine·2022· 2 citedOpen Access
Calprotectin (S100A8/S100A9) detects inflammatory activity in rheumatoid arthritis patients receiving tocilizumab therapy
Arthritis Research & Therapy·2022· 23 citedOpen Access
Clinical Utility of C-Reactive Protein and White Blood Cell Count for Scheduling an [18F]FDG PET/CT in Patients with Giant Cell Arteritis
Nuklearmedizin - NuclearMedicine·2022· 3 cited
POS1013 HOW DOES BODY MASS INDEX AFFECT SECUKINUMAB TREATMENT OUTCOMES AND SAFETY IN PATIENTS WITH PSORIATIC ARTHRITIS? – REAL WORLD DATA FROM THE GERMAN AQUILA STUDY
Annals of the Rheumatic Diseases·2022· 1 citedOpen Access
Responses to Ixekizumab in Male and Female Patients with Psoriatic Arthritis: Results from Two Randomized, Phase 3 Clinical Trials
Rheumatology and Therapy·2022· 15 citedOpen Access
Immunosuppressive Therapy After Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients—High Efficacy of Rituximab
Frontiers in Immunology·2022· 12 citedOpen Access
Sarilumab reduces disease activity in rheumatoid arthritis patients with inadequate response to janus kinase inhibitors or tocilizumab in regular care in Germany
Rheumatology Advances in Practice·2022· 16 citedOpen Access
High Prevalence of Genital Human Papillomavirus Infection in Patients With Primary Immunodeficiencies
Frontiers in Immunology·2021· 9 citedOpen Access
Whole-Body [18F]FDG PET/CT Can Alter Diagnosis in Patients with Suspected Rheumatic Disease
Diagnostics·2021· 6 citedOpen Access
page 1 of 12Next →

Frequent Co-authors

Thomas Dörner(10), Marc Schmalzing(7), Petra Roll(7), Hendrik Schulze‐Koops(7), Siegfried Wassenberg(7), Stefan Kleinert(7), Gerd R Burmester(6), Andrea Rubbert‐Roth(6), Christof Specker(6), Rieke Alten(6), Martin Feuchtenberger(6), Ulf Müller‐Ladner(5), Martin Fleck(5), Andreas Krause(5), Bernhard Manger(5), Christian Kneitz(4), Christoph Baerwald(4), H. Nüßlein(4), Matthias Englbrecht(4), Jürgen Rech(4)